| 產品名稱 |
pCC4 |
| 商品貨號 |
B173379 |
| Designations |
pCC4 |
| Species |
Homo sapiens, human |
| Depositors |
City University of New York, DH Calhoun, City University of New York |
| Vector |
Construct size (kb): 11.19999980926514 |
| Insert |
DNA: cDNA Insert lengths(kb): 1.399999976158142 Tissue: liver Gene product: galactosidase, alpha( alpha-galactosidase, alpha-D-galactosidase A, alpha-galactosidase (melibiase)) [GLA] |
| Insert Size (kb) |
1.400 |
| Media |
ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin
|
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Shipping Information |
Shipped: ?Freeze dried stock of Escherichia coli containing the plasmid. |
| Comments |
Restriction digests of the clone give the following sizes (kb): BamHI--9.8, 1.4; EcoRI--6.6, 3.4, 1.35; NotI--uncut. ATCC 68266 differs from ATCC 68267 in that 68266 contains wild-type GLA and 68267 contains a modified GLA that permits 1000-fold increased expression. Recommendation for verification: BamHI--1.4, 9.8; EcoRI; NotI. |
| References |
Calhoun DH, Coppola G. Recombinant alpha-galactosidase A therapy for Fabry disease. US Patent 5,179,023 dated Jan 12 1993
|
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
